Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition.
about
Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice.Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid.Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition.Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice.Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancerTarget-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.Model-based clinical drug development in the past, present and future: a commentary.A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals.
P2860
Q33383483-3E2A4DE1-36D5-4C0B-8082-0B4D8DAEA781Q34028124-5E8E22CB-2BF0-4ACF-896B-14ED15F2781CQ34293586-9FE9ED36-D503-496A-9B72-F47F8E2A9F79Q34901079-814AA3AE-3169-466D-94D4-A96C18134499Q35168120-A6316272-D2FE-479C-83CF-36B26BCABF4DQ35168311-1602476D-AB74-426F-A058-B3CA0E7E00B2Q35206798-BC551C7D-13DB-4A85-B3BC-D2092287C05BQ36502390-F73A8686-E625-4126-B037-70A6FC1A52D7Q37054801-E4959082-053D-4A0C-8DA3-C27A7F5DAC85Q37510861-7EA3BA8E-9CA5-4E89-BA70-750DA002F9A6Q38188035-D605F02A-682C-4942-A4B8-0191EC611F32Q42351659-C2027742-77E3-4251-8B84-EE6D6B449137Q46358056-E77A316E-AE5B-43A0-A1DC-C70715BEC8D4
P2860
Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 June 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Partial derivative-based sensi ...... get-mediated drug disposition.
@en
Partial derivative-based sensi ...... get-mediated drug disposition.
@nl
type
label
Partial derivative-based sensi ...... get-mediated drug disposition.
@en
Partial derivative-based sensi ...... get-mediated drug disposition.
@nl
prefLabel
Partial derivative-based sensi ...... get-mediated drug disposition.
@en
Partial derivative-based sensi ...... get-mediated drug disposition.
@nl
P2093
P2860
P356
P1433
P1476
Partial derivative-based sensi ...... get-mediated drug disposition.
@en
P2093
Anson K Abraham
Donald E Mager
Wojciech Krzyzanski
P2860
P2888
P304
P356
10.1208/AAPSJ0902020
P407
P577
2007-06-08T00:00:00Z
P5875
P6179
1014241235